The NeuraMetrix solution provides Biopharmaceutical companies with a much more precise, accurate, and cost-effective Digital Cognitive Biomarker for Clinical Drug Development
The gap
The main issues for drug trials within neurological diseases and psychiatric disorders today are:
Do not have good and early indicators of safety and efficacy
Difficult to successfully develop new drugs when the cohort is based on patients where the disease has already progressed beyond where the drugs can have an impact
No ability to monitor "in real-time" the effect on each trial participant
Difficult to measure cognitive side effects of their drugs
NeuraMetrix' highly precise and easy to implement digital biomarker fills an important gap long sought after by the biotech and pharmaceutical industry
With the NeuraMetrix digital biomarker drug trials for neurological diseases and psychiatric disorders can:
Have earlier, more sensitive and less variable indicators of safety and efficacy
Get objective sensitive measures of disease state, disease progression and response to therapy in clinic and at home
Identify patient segmentation strategies
Granular quantification of disease symptoms
Detect known drug effect by monitoring drug compliance
This enables biotech and pharmaceutical companies to:
Smaller, shorter duration of clinical trials
Make it easier for the cohort
Increase prognostic enrichment: selection of patients at high risk of disease-related endpoints
Increase predictive enrichment: selection of patients sub segment with disease stages more likely to drug treatment
Narrow the range of scores for inclusion into a trial
Have trials designs which include pre-randomization baseline "run-in" period to exclude patients whose symptoms resolve spontameously or have highly variable baseline symptoms
Identify patients likely to adhere to treatment
Identify responders vs. non-responders by quantifying patient symptoms and track longitudinally
Resulting in:
Faster go/no go decisions
Decreased variability
Decreased heterogeneity
Increased study power
Better management of drug trials
Fewer participants dropping out of drug trials
Less risk
Less cost
Headquarters
NeuraMetrix, Inc. 725 Merrimon Ave #8845 Asheville, NC 28814, U.S.A.
NeuraMetrix is a Medical Device company. It offers a novel, unique, highly accurate digital biomarker to detect and monitor a range of Neurological diseases and Psychiatric disorders.